Over the past few years, we have seen the alphabet soup of triplet and quadruplet therapies for multiple myeloma explode. Today we will be adding another : IberVd.
The Vd part is an acronym that is familiar to just about all of us myeloma patients: Velcade-dexamethasone.
The “Iber” part stands for “iberdomide”, a compound that has been in clinical trials already for several years and with quite a few scientific papers now discussing the outcomes of these trials.
Iberdomide, also known as CC-220, is a compound that Bristol Myers added to its myeloma armamentarium with the acquisition of Celgene (past marketers of Thalomid, Revlimid and Pomalyst and the developers of the anti-BCMA CAR-T product Abecma).
Iberdomide is a member of “the CRBN (Cereblon) E3 ligase modulators (CELMoDs), the next generation of IMiDs (immunomodulators such as e.g., Revlimid) with broader biological activity [than Revlimid/Pomalyst].”
Bristol-Myers/Celgene started the clinical studies of iberdomide in October 2016 under a very complex but also very complete study design. Apart from evaluating iberdomide as a monotherapy, the company also included study arms for the following combinations with iberdomide :
This post, however, will be limited to the discussion of the group of newly diagnosed patients given the combination of IberVd, as presented at the recent International Society Myeloma meeting in Athens, Greece1.
The dosing schedule is very similar to what many of us have seen in a Velcade-Revlimid-dexamethasone (VRd) induction program following our diagnosis with myeloma :
The noted side effects were very similar to those seen with the VRd combo.
In summary, “These data support further assessment of iberdomide combinations in the frontline setting”.
Iberdomide has all the makings of becoming an exciting addition to the treatment options for myeloma patients.
Unfortunately, we will have to wait a few more years for this compound to complete its clinical program and for Bristol to compile a regulatory dossier and submit it for review with the FDA, before this drug can be commercialized.
Other articles on iberdomide:
Over the past few years, we have seen the alphabet soup of triplet and quadruplet therapies for multiple myeloma explode. Today we will be adding another : IberVd.
The Vd part is an acronym that is familiar to just about all of us myeloma patients: Velcade-dexamethasone.
The “Iber” part stands for “iberdomide”, a compound that has been in clinical trials already for several years and with quite a few scientific papers now discussing the outcomes of these trials.
Iberdomide, also known as CC-220, is a compound that Bristol Myers added to its myeloma armamentarium with the acquisition of Celgene (past marketers of Thalomid, Revlimid and Pomalyst and the developers of the anti-BCMA CAR-T product Abecma).
Iberdomide is a member of “the CRBN (Cereblon) E3 ligase modulators (CELMoDs), the next generation of IMiDs (immunomodulators such as e.g., Revlimid) with broader biological activity [than Revlimid/Pomalyst].”
Bristol-Myers/Celgene started the clinical studies of iberdomide in October 2016 under a very complex but also very complete study design. Apart from evaluating iberdomide as a monotherapy, the company also included study arms for the following combinations with iberdomide :
This post, however, will be limited to the discussion of the group of newly diagnosed patients given the combination of IberVd, as presented at the recent International Society Myeloma meeting in Athens, Greece1.
The dosing schedule is very similar to what many of us have seen in a Velcade-Revlimid-dexamethasone (VRd) induction program following our diagnosis with myeloma :
The noted side effects were very similar to those seen with the VRd combo.
In summary, “These data support further assessment of iberdomide combinations in the frontline setting”.
Iberdomide has all the makings of becoming an exciting addition to the treatment options for myeloma patients.
Unfortunately, we will have to wait a few more years for this compound to complete its clinical program and for Bristol to compile a regulatory dossier and submit it for review with the FDA, before this drug can be commercialized.
Other articles on iberdomide:
about the author
Paul Kleutghen
I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find successful treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and two grandsons who are the ‘lights of our lives’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs. I am a firm believer that staying mentally active, physically fit, compliant to our treatment regimen and taking an active interest in our disease are keys to successful treatment outcomes.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.